AN2 Therapeutics
ANTX
38 hedge funds and large institutions have $165M invested in AN2 Therapeutics in 2022 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 16 increasing their positions, 12 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
128% more capital invested
Capital invested by funds: $72.4M → $165M (+$92.6M)
33% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 12
6% more funds holding
Funds holding: 36 → 38 (+2)
0.57% more ownership
Funds ownership: 48.39% → 48.95% (+0.57%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$633K |
| 2 |
Citigroup
New York
|
+$545K |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$293K |
| 4 |
Barclays
London,
United Kingdom
|
+$261K |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$201K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
-$363K |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$225K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$225K |
| 4 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
-$165K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$119K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
JP Morgan Chase
New York
| $46K | +$1.69K | +145 | +6% |
|
|
AIG
27
American International Group
New York
| $40K | +$1.26K | +108 | +5% |
|
28
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $33K | -$3.61K | -310 | -14% |
|
29
California State Teachers Retirement System (CalSTRS)
West Sacramento,
California
| $33K | -$1.03K | -88 | -4% |
|
|
AB
30
Amalgamated Bank
New York
| $24K | +$70 | +6 | +0.4% |
|
|
TRCT
31
Tower Research Capital (TRC)
New York
| $22K | -$35.9K | -3,083 | -71% |
|
32
Legal & General Group
London,
United Kingdom
| $7K | – | – | – |
|
|
AIP
33
Ameritas Investment Partners
Lincoln,
Nebraska
| $6K | – | – | – |
|
34
Osaic Holdings
Scottsdale,
Arizona
| $3K | – | – | – |
|
35
Royal Bank of Canada
Toronto,
Ontario, Canada
| $1K | +$373 | +32 | +119% |
|
|
PAG
36
Private Advisor Group
Morristown,
New Jersey
| – | -$165K | -11,001 | Closed |
|
37
Wells Fargo
San Francisco,
California
| – | -$536 | -46 | -63% |
|
38
Fidelity Investments
Boston,
Massachusetts
| – | +$187 | +16 | New |
|
|
CS
39
Credit Suisse
Zurich,
Switzerland
| – | +$280 | +24 | +1,200% |
|
ANTX Hedge Fund Activity: Q3 2022 in Review
38 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in AN2 Therapeutics (ANTX) for Q3 2022, worth a combined $165M — up 128% from $72.4M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new ANTX positions and 1 closed out — a net gain of 2 holders — while 16 added to existing stakes and 12 trimmed.
The largest buyer was Avidity Partners Management, adding an estimated $633K. The largest seller was Woodline Partners, cutting an estimated $363K.
- 38 institutional investors held AN2 Therapeutics (ANTX) as of Q3 2022, up from 36 in Q2 2022.
- Funds reported $165M of AN2 Therapeutics stock for Q3 2022, up 128% quarter-over-quarter.
- 3 funds opened new AN2 Therapeutics positions in Q3 2022 and 1 closed out, a net change of +2 holders.
- The largest AN2 Therapeutics buyer in Q3 2022 was Avidity Partners Management, an estimated $633K added.
- The largest AN2 Therapeutics seller in Q3 2022 was Woodline Partners, an estimated $363K sold.
Based on aggregated 13F filings for Q3 2022.